Clinical and radiological pivotal data
CIS

Adapted from Jacobs et al. 1996.


Three hundred one patients with RMS were randomised into a double-blinded, placebo-controlled, multicenter phase 3 trial of interferon-beta-1a.

 

*Calculated using the first 104 weeks of data for patients accrued early enough to complete 104 weeks of follow-up.


ARR: Annualised Relapse Rate; CDMS: Clinically Definite Multiple Sclerosis; EDSS: Expanded Disability Status Scale; Gd+: Gadolinium Enhancing; MRI: Magnetic Resonance Imaging.

~ 8 Out of 10 patients who had high risk CIS on Avonex had an EDSS <3.0 Over 10 years1*

Adapted from Kinkel et al. 2012.


31% of Avonex-treated patients with high risk CIS experienced no relapses over 10 years1*

Adapted from Kinkel et al. 2012.

 

 

 

* Data are from 10-year follow up of the CHAMPIONS/CHAMPS studies in high-risk patients who had a clinically isolated syndrome (CIS). 

† Total mean ARR of 0.22 for patients between years 5 and 10 across both treatment groups in CHAMPIONS 10-year follow-up (n=127). Data are from 10-year follow up of the CHAMPIONS/CHAMPS studies in high-risk patients who had a clinically isolated syndrome (CIS).


ARR: Annualised Relapse Rate; EDSS: Expanded Disability Status Scale.

Biogen-36608. Date of preparation: January 2020